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Background: Tolosa-Hunt syndrome is a rare clinical syndrome characterized by painful ophthalmoplegia and
ipsilateral cranial neuropathies. It is caused by an inflammatory process of unknown etiology.
Case presentation: We present a case of a 77-year-old white man with history of Waldenstrom’s macroglobulinemia
transforming to large B-cell lymphoma who presented to a community physician complaining of 4 months of isolated
right retro-orbital pain and later with diplopia, ptosis, 6th nerve and pupil-sparing partial 3rd nerve palsies as well as
progressive neurological findings. His clinical course was complicated by debilitating neurological symptoms and
multiple hospitalizations leading to a delay in diagnosis caused by incomplete initial workup.
Conclusion: This case is a reminder that lymphoproliferative disorders often mimic other neurologic disorders and
that Tolosa-Hunt is a rare diagnosis that must be considered a diagnosis of exclusion.
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Tolosa-Hunt syndrome (THS) is a rare clinical syn-
drome characterized by painful ophthalmoplegia and
ipsilateral cranial neuropathies [1-7]. It is caused by an
idiopathic granulomatous inflammation of the cavernous
sinus or orbital apex complex that is exquisitely respon-
sive to parentral glucocorticoids. The estimated annual
incidence is one case per million per year in the US [3].
This rare clinical entity was first described in 1954 as a
syndrome comprised of two features: (a) pain in the first
division of the trigeminal nerve; and (b) progressive par-
alysis, partial or total, of the oculomotor nerve and occa-
sionally of the fourth, sixth, and the fifth cranial nerves
[1]. Tolosa-Hunt syndrome is a diagnosis of exclusion
and must be carefully differentiated from life threatening
diagnoses, a mandate challenged by the lack of a specific
diagnostic test to identify this disorder [3].
Tolosa-Hunt syndrome is caused by an inflammatory
process of unknown etiology [4]. The inflammation leads
to compression and secondary dysfunction of the struc-
tures within the cavernous sinus, including cranial nerves
III, IV, and VI, as well as the ophthalmic and maxillary* Correspondence: shazlyt@gmail.com
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symptoms [1-7].
Case presentation
A cachectic 77 year-old white male with history of
Waldenstrom’s macroglobulinemia transforming to large
B-cell lymphoma presented with right eye pain for 4
months without any visual symptoms. He is an ex-
smoker with 0.5 packs per day over 30 years of tobacco
smoking (quit in 2003). He currently is retired and lives
with his wife. He denies consuming alcohol or controlled
substances.
On day 1 of his symptoms he presented to a commu-
nity physician with right retro-orbital pain. A Magnetic
Resonance Imaging (MRI) scan of the brain with IV
contrast was ordered given his history of lymphoma. His
MRI was negative for acute pathology. Given his nega-
tive scan and the severity of pain, he was treated with
oral valacyclovir along with prednisone for presumed
right Herpes Zoster ophthalmicus.
One week later, he presented urgently to a local emer-
gency room for a new onset of diplopia and right eyelid
ptosis. His examination was significant for a right partial,
pupil involving third nerve palsy. A repeat MRI of the
brain and orbits with IV contrast was obtained, and
revealed right lacrimal gland enlargement. A lumbarThis is an Open Access article distributed under the terms of the Creative
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tive for abnormal cells, leading to a presumptive diagnosis
of right sided Tolosa Hunt Syndrome. He received the
presumptive diagnosis of right sided Tolosa-Hunt Syn-
drome. He received a dose of 500 mg of intravenous
(IV) methylprednisolone in the emergency room which
achieved a prompt and significant reduction in his pain
level. His blood sugar level became elevated in response
to the IV steroids. He was discharged to home with the
instructions to use 60 mg of oral prednisone and an insu-
lin sliding scale until he was seen by his primary care
physician.
Four weeks later, he saw his local ophthalmologist for
persistent diplopia despite complete resolution of his
pain and ptosis. At that time, he was on 10 mg/day of
prednisone. He had developed severe, progressive muscle
weakness due to steroid induced myopathy and was con-
fined to a wheelchair. He then underwent surveillance
Positron Emission Tomography – Computed Tomog-
raphy (PET-CT) for lymphoma. The scan incidentally
revealed asymptomatic perforated diverticulitis. He was
urgently admitted to the hospital and had a prolonged
hospital course with conservative treatment, including IV
Piperacillin/Tazobactam, nil per os (NPO) and gradual
Prednisone taper, with discharge to home on Prednisone
5 mg/day.
Less than a week later he developed a new non-productive
cough. Chest computed tomography (CT) revealed interval
lung consolidation. Lung biopsy was performed and revealed
Pneumocystis carinii for which he received a 3 week
course of atovaquone.
Four weeks later (Week 10 of symptoms), he was re-
ferred to the Neuro-ophthalmology division for evaluationFigure 1 PET-CT Contrast-enhanced helical CT was performed and PET em
A: Shows a new focus of abnormal metabolic activity at the lateral wall the
B: Shows area of dense consolidation with high metabolic activity suggesti
multiple hot spots involving the R. parotid, mandibular angle, lateral wall thof persistent 3rd cranial nerve palsy with negative neuro-
imaging. At that time his only ocular symptom was
binocular diplopia. On examination his visual acuity and
color vision were normal in each eye, with full Humphrey
visual fields. His motility exam was significant for bilateral
6th nerve palsies and left partial pupil sparing 3rd nerve
palsy. Given the high suspicion for lymphomatous infiltra-
tion despite the negative prior neuroimaging, a repeat
brain and orbit MRI as well as LP were obtained and were
both unrevealing.
The case was extensively discussed with the patient’s
oncologist, local ophthalmologist and neurologist, how-
ever, they opted to continue present management. He
was then lost to follow up for 7 weeks before his return
visit with the complaints of unchanged diplopia and new
right sided facial dysthesia, worsened right ptosis and
return of his his right eye pain. His exam now revealed a
right pupil involving 3rd nerve palsy, right facial palsy,
and sensation was decreased over right V1, V2 and V3.
Given the progression of his cranial neuropathies, he
was admitted for repeat brain and orbit MRI, LP, and
CT Angiography of the head and neck. These tests were
initially interpreted as unrevealing.
Two weeks later, his routine PET/CT revealed a new
focus of abnormal metabolic activity involving the lateral
wall the right orbit, with underlying sclerosis. It also
revealed an area of dense lung consolidation with high
metabolic activity suggestive of malignancy (Figure 1).
Additionally, multiple hot spots involving the right
parotid, mandibular angle, lateral wall the sternum, both
humeri and femurs were detected. An urgent MRI of the
brain and orbit revealed asymmetric enhancement involv-
ing Meckel’s cave along the V3 division of the rightission data 1 hour following IV injection of 18.1 mCi of F-18 FDG.
right orbit with underlying sclerosis. Maximal SUV value is 4.6.
ve of malignancy rather than an infection or inflammation. Additionally,
e R. orbit, sternum, both humeri and femurs were detectable.
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tumor (Figure 2). Overlying the right parotid gland, there
was a new 22 × 13 mm heterogeneously enhancing lymph
node. An enhancing, bone marrow-replacing lesion
within the left aspect of the clivus, with involvement of
the right aspect of the sphenoid floor, and lesions adjacent
to the right carotid canal.
Parotid fine needle aspiration biopsy revealed diffuse
large B-cell non-Hodgkin lymphoma with high-grade fea-
tures. Chemotherapy with Gemcitabine, Dexamethasone,
and Rituximab was initiated along with 3D conformal
radiation of the orbit with good response.
Five months later, his diplopia and ocular motility were
slightly improved. He developed exposure keratopathy
with stable visual acuity and no evidence of radiation
retinopathy. He was then referred to adult strabismus
service for definitive treatment of his residual binocular
diplopia.
Discussion
In 1988, the International Headache Society defined the
diagnostic criteria of THS to include; episode(s) of uni-
lateral orbital pain for an average of 8 weeks if untreated,
with associated paresis of one or more of the third,
fourth, and sixth cranial nerves. Cranial nerve paresis
may coincide with the onset of pain or follow it within a
period of up to 2 weeks, and the pain must be relieved
within 72 hours of initiation of corticosteroid therapy.
Other causative space-occupying or infiltrative lesions
must be excluded by neuro-imaging. Förderreuther et al.
reported 6 cases were the aforementioned criteria mis-
lead to the diagnosis of THS in the presence of other
pathology, and recommended revising the criteria. In hisA
Figure 2 MRI Brain and orbit with and without contrast. A: asymmetric en
trigeminal nerve suggestive of perineural spread of tumor. B: overlying the
enhancing lymph node.series, the 6 patients were found to have a parasellar
chondrosarcoma, inconclusive pathological exam of
cavernous sinus mass due to small sample, chordoma
extending into the cavernous sinus, suspected meningi-
oma versus THS, diabetic microvascular third nerve
palsy, and cerebral vasculitis. He included “Other causa-
tive lesions must be excluded by neuro-imaging, espe-
cially of the region of the cavernous sinus and the orbita,
and by blood and cerebrospinal fluid (CSF) examinations”
[8]. They also recommended that clinical and radiological
follow-up examinations must be performed for at least 2
years, even in patients with negative findings on magnetic
resonance imaging at onset.
Orbital lymphomas are relatively rare, comprising only
1% of all non-Hodgkin’s lymphoma [9]. However, orbital
lymphomas are the most common primary orbital tumor
in adults 60 years of age and older [10]. Margo and
Mulla reported a 55% rate of lymphomas involving the
orbit amongst 300 patients with orbital malignancies
[11]. Eckardt et al. reported diagnostic delay in patients
with orbital lymphoma due to the non-specific presenta-
tion [12]. Once diagnosis is established and staging is
complete, radiation therapy is the recommended treat-
ment for stage IEA patients. Systemic chemotherapy is
indicated in selected stage IIEA patients and in patients
with stage IIIEA disease [12].
Our patient was started on corticosteroids for two
different presumptive diagnoses: Herpes Zoster Ophthal-
micus and THS. The prolonged steroid course caused a
number of complications, including myopathy, pneumo-
nia, and hyperglycemia, and delayed treatment of his
underlying malignancy. This case is a reminder that
Tolosa-Hunt Syndrome (THS) is a rare disorder andB
hancement in the right Meckels cave along the V3 division of the
right parotid gland, there is a new 22 × 13 mm heterogeneously
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vision-threatening conditions may mimic THS. These
conditions should be carefully excluded prior to consid-
ering empiric corticosteroid therapy. It should also be
remembered that corticosteroid not only improves the
signs and symptoms of THS but may mask a number of
neoplastic, inflammatory and lymphoproliferative dis-
orders, delaying definitive treatment or diagnosis [8].
Additionally, any diagnosis of THS should be chal-
lenged when clinical worsening occurs after parenteral
steroids.
Conclusion
A high index of suspicion is indicated to exclude neopla-
sia and any lymphoproliferative disorder in high risk
patients with evolving multiple cranial neuropathies.
New or evolving findings on successive clinical exams,
particularly after treatment with parenteral steroids,
should prompt neuroimaging and extensive diagnostic
testing to exclude malignancy or a space-occupying lesion
mimicking THS. Tolosa-Hunt should remain a diagnosis
of exclusion.
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